Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gareth Pryce

Showing results (21-30 of 65) with videos related to

Pageof 7
Sort By:
Multiple Sclerosis and Related Disorders|July 10, 2020
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosisDavid Baker, Gareth Pryce, Louisa K James, et al.
Pharmaceuticals (Basel, Switzerland)|July 29, 2023
Neuroprotection in an Experimental Model of Multiple Sclerosis via Opening of Big Conductance, Calcium-Activated Potassium ChannelsGareth Pryce, Sofia Sisay, Gavin Giovannoni, et al.
Autoimmunity|January 27, 2012
Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitisSharmilee Gnanapavan, Donna Grant, Gareth Pryce, et al.
Multiple Sclerosis and Related Disorders|October 8, 2021
Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case reportMonica Marta, David Baker, Paul Creeke, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 5, 2011
Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitisSarah Al-Izki, Gareth Pryce, Samuel J Jackson, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|December 25, 2014
Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based CannabinoidsGareth Pryce, Dieter R Riddall, David L Selwood, et al.
The American Journal of Pathology|July 29, 2005
A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitisEmma East, David Baker, Gareth Pryce, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 11, 2003
Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitisJohn Greenwood, Claire E Walters, Gareth Pryce, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 2, 2011
Paracetamol-induced hypothermia is independent of cannabinoids and transient receptor potential vanilloid-1 and is not mediated by AM404Samir S Ayoub, Gareth Pryce, Michael P Seed, et al.
Multiple Sclerosis and Related Disorders|December 5, 2022
The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccinationDavid Baker, Eugenia Forte, Gareth Pryce, et al.
Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
Multiple Sclerosis and Related Disorders|July 10, 2020
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosisDavid Baker, Gareth Pryce, Louisa K James, et al.
Pharmaceuticals (Basel, Switzerland)|July 29, 2023
Neuroprotection in an Experimental Model of Multiple Sclerosis via Opening of Big Conductance, Calcium-Activated Potassium ChannelsGareth Pryce, Sofia Sisay, Gavin Giovannoni, et al.
Autoimmunity|January 27, 2012
Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitisSharmilee Gnanapavan, Donna Grant, Gareth Pryce, et al.
Multiple Sclerosis and Related Disorders|October 8, 2021
Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case reportMonica Marta, David Baker, Paul Creeke, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 5, 2011
Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitisSarah Al-Izki, Gareth Pryce, Samuel J Jackson, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|December 25, 2014
Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based CannabinoidsGareth Pryce, Dieter R Riddall, David L Selwood, et al.
The American Journal of Pathology|July 29, 2005
A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitisEmma East, David Baker, Gareth Pryce, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 11, 2003
Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitisJohn Greenwood, Claire E Walters, Gareth Pryce, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 2, 2011
Paracetamol-induced hypothermia is independent of cannabinoids and transient receptor potential vanilloid-1 and is not mediated by AM404Samir S Ayoub, Gareth Pryce, Michael P Seed, et al.
Multiple Sclerosis and Related Disorders|December 5, 2022
The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccinationDavid Baker, Eugenia Forte, Gareth Pryce, et al.
Pageof 7